ProCE Banner Activity

An Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies

Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 experts in managing patients with hematologic malignancies.

Released: December 06, 2021

Expiration: December 05, 2022

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Nicole Lamanna

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Additional Information

Program Medium

This program has been made available online.